<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nat Sci Biol Med</journal-id><journal-id journal-id-type="iso-abbrev">J Nat Sci Biol Med</journal-id><journal-id journal-id-type="publisher-id">JNSBM</journal-id><journal-title-group><journal-title>Journal of Natural Science, Biology, and Medicine</journal-title></journal-title-group><issn pub-type="ppub">0976-9668</issn><issn pub-type="epub">2229-7707</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26604599</article-id><article-id pub-id-type="pmc">4630743</article-id><article-id pub-id-type="publisher-id">JNSBM-6-123</article-id><article-id pub-id-type="doi">10.4103/0976-9668.166116</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saha</surname><given-names>Monimala</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Chakraborty</surname><given-names>Aparna</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Chattopadhyay</surname><given-names>Sandip</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Saha</surname><given-names>Subhendu</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>Joydip</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Anjan</given-names></name><xref ref-type="aff" rid="aff4">3</xref><xref ref-type="corresp" rid="cor1"></xref></contrib></contrib-group><aff id="aff1"><italic>Department of Gynecology and Obstetrics, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India</italic></aff><aff id="aff2"><label>1</label><italic>Department of Gynecology and Obstetrics, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India</italic></aff><aff id="aff3"><label>2</label><italic>Department of Pediatric Medicine, Malda Medical College, Malda, West Bengal, India</italic></aff><aff id="aff4"><label>3</label><italic>Department of Anaesthesiology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India</italic></aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold><italic> Dr. Anjan Das, 174, Gorakshabashi Road, Royal Plaza Apartment (4<sup>th</sup> Floor, Flat No-1), Nagerbazar, Kolkata - 700 028, West Bengal, India. E-mail: <email xlink:href="anjan2k8@yahoo.com">anjan2k8@yahoo.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2015</year></pub-date><volume>6</volume><issue>Suppl 1</issue><fpage>S123</fpage><lpage>S127</lpage><permissions><copyright-statement>Copyright: © Journal of Natural Science, Biology and Medicine</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4008" xml_f="4019" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4030" xml_f="4305" txt_i="23" txt_f="298">Misoprostol is very effective in cervical ripening and is used for termination of pregnancy. A similar effect on the nonpregnant uterus will facilitate gynecological operations, and hence we assessed the effect of misoprostol on the nonpregnant uterus of premenopausal women.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4336" xml_f="4358" txt_i="300" txt_f="322">Materials and Methods:</offsets></title><p><offsets xml_i="4369" xml_f="4720" txt_i="323" txt_f="674">In a prospective double-blinded randomized controlled trial, 280 women were randomly allocated into two groups (12 women did not complete the intervention). Study (A) and control (B) group received 400 μg of misoprostol or 400 mg of metronidazole tablets (as a placebo) respectively in the posterior vaginal wall 6 h prior to gynecological procedures.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4751" xml_f="4759" txt_i="676" txt_f="684">Results:</offsets></title><p><offsets xml_i="4770" xml_f="4825" txt_i="685" txt_f="740">The mean cervical dilatation was significantly higher (</offsets><italic><offsets xml_i="4833" xml_f="4834" txt_i="740" txt_f="741">P</offsets></italic><offsets xml_i="4843" xml_f="5399" txt_i="741" txt_f="1294"> &lt; 0.0001) in misoprostol compared to placebo group (4.6 ± 0.96 mm vs. 3.6 ± 0.82 mm), benefit were also observed on secondary outcome measures which were need for further dilatation, time taken for further dilatation, ease of dilatation, subjective assessment of pain by visual analog scale. Only 3.61% patients complained of intolerable pain during dilatation in the study group while in control group 48.74% complained of intolerable pain and required anesthesia. Most common side effects of misoprostol were abdominal pain and mild vaginal bleeding.</offsets></p></sec><sec id="st4"><title><offsets xml_i="5430" xml_f="5441" txt_i="1296" txt_f="1307">Conclusion:</offsets></title><p><offsets xml_i="5452" xml_f="5574" txt_i="1308" txt_f="1430">Misoprostol was effective in cervical ripening of nonpregnant premenopausal uterus to facilitate gynecological procedures.</offsets></p></sec></abstract><kwd-group><kwd>Cervical dilatation</kwd><kwd>misoprostol</kwd><kwd>nonpregnant</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5762" xml_f="5774" txt_i="1439" txt_f="1451">INTRODUCTION</offsets></title><p><offsets xml_i="5785" xml_f="5930" txt_i="1452" txt_f="1597">Misoprostol is extensively used in obstetrics and has proved to be very effective cervical softening agent necessary intermination of pregnancy.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5963" xml_f="5964" txt_i="1597" txt_f="1598">1</offsets></xref><xref rid="ref2" ref-type="bibr"><offsets xml_i="6004" xml_f="6005" txt_i="1598" txt_f="1599">2</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="6045" xml_f="6046" txt_i="1599" txt_f="1600">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="6086" xml_f="6087" txt_i="1600" txt_f="1601">4</offsets></xref><offsets xml_i="6094" xml_f="6600" txt_i="1601" txt_f="2107">] However, a similar beneficial effect of misoprostol on the nonpregnant uterus, will facilitate gynecological procedures that require cervical dilation such as endometrial biopsy, hysteroscopy, chromotubation, etc. Further the complications related to these procedures such as excessive pain, cervical injury may be reduced. Thus, most of the minor gynecological procedures may be performed without general anesthesia, which will lead to decreased hospital stay and hence reduce the cost of the procedure.</offsets></p><p><offsets xml_i="6607" xml_f="7459" txt_i="2108" txt_f="2960">To facilitate cervical dilatation paracervical analgesia block or nonsteroidal anti-inflammatory drugs are commonly used before the procedure. Secondly in a difficult situation caused by cervical anatomic changes it would be worthwhile if there were a way to change intrinsically the cervix to make the dilatation easier. Misoprostol, a synthetic prostaglandin analog is found to be a very useful drug in obstetrics and gynecology. Following the vaginal application peak plasma concentration of misoprostol is reached in 1-2 h. The most common side effects of misoprostol are nausea, vomiting, diarrhea, abdominal cramps and fever, which are, dose-dependent. These side effects are, however, reduced if tablets are given vaginally compared to oral administration. Misoprostol causes strong myometrial contraction and cervical softening and dilatation.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7492" xml_f="7493" txt_i="2960" txt_f="2961">5</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="7533" xml_f="7534" txt_i="2961" txt_f="2962">6</offsets></xref><offsets xml_i="7541" xml_f="8032" txt_i="2962" txt_f="3453">] Although the beneficial effects of misoprostol can be hypothesized on the nonpregnant uterus as well, only a few studies have tested this. Hence, this study was designed to evaluate the beneficial effects of misoprostol on nonpregnant premenopausal uterine cervix prior to some gynecological procedures that is, to decrease the cervical resistance and facilitate the mechanical cervical dilation, to minimize the cervical or uterine injury and to decrease the pain of dilatation procedure.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="8095" xml_f="8116" txt_i="3455" txt_f="3476">MATERIALS AND METHODS</offsets></title><p><offsets xml_i="8127" xml_f="9461" txt_i="3477" txt_f="4805">This randomized controlled trial was conducted from April 2009 to March 2010 in a tertiary care hospital. Following Ethical Committee approval, written and informed consent was obtained from all patients. Patients aged 20-55 years and American Society of Anesthesiologists Physical Status I, II scheduled to have diagnostic D and C or hysteroscopy for different indications, were included in the study. Exclusion criteria included postmenopausal woman, H/O bronchial asthma, allergy to prostaglandin E1, irritable bowel disease, cardiovascular diseases, patient refusal, known allergy or hypersensitivity or contraindication to prostaglandins, impaired liver function (transaminases &gt; twice upper limit), renal dysfunction (creatinine &gt;2.0 mg/dl), uncontrolled chronic diseases, known or suspected history of drug abuse. Proper history regarding chief complains detailed clinical examination, including general and systemic examinations and routine baseline investigations were performed. Preoperative fasting of minimum 6 h was ensured before the operation, and all patients were admitted on the day before the operation in all day care cases. Patients received oral premedication, 10 mg diazepam on the night before surgery and tablet ranitidine 150 mg in the previous night and in the morning of operation with sips of water.</offsets></p><p><offsets xml_i="9468" xml_f="10187" txt_i="4806" txt_f="5525">The patients were randomly allocated into two parallel Groups A and B with 135 patients in the study group (Group A) and 133 patients in the control group (Group B) using computer generated randomization protocol. The patients in the study group received 400 μg of misoprostol (two 200 μg misoprostol tablets) while control group received 400 mg of metronidazole (two 200 mg of metronidazole uncoated tablet) 6 h prior to operative procedure. Drugs were administered in all women by on-duty resident doctor without showing the drugs to the patients. Drugs were supplied to the ward as per randomization schedule on the day of admission in the identical sealed envelope mentioning the registration number of the patient.</offsets></p><p><offsets xml_i="10194" xml_f="10800" txt_i="5526" txt_f="6132">Normal saline vaginal wash was given in all patients by the on-duty nursing staff to remove any remnant of the drug before sending the patient to the operation theater. There was no discussion regarding the procedure with those persons who had supplied the drug and those resident doctors who had applied the same till completion of the study. The operative procedure was started without using any analgesia or anesthesia. Primary outcome measure was assessed by the largest size Hegar's dilators that could be inserted without resistance at the beginning of the surgical procedure. Secondary outcome were:</offsets></p><p><offsets xml_i="10807" xml_f="10808" txt_i="6133" txt_f="6134">
</offsets><list list-type="simple"><list-item><label><offsets xml_i="10851" xml_f="10854" txt_i="6134" txt_f="6137">(1)</offsets></label><p><offsets xml_i="10865" xml_f="10893" txt_i="6137" txt_f="6165">Need for further dilatation,</offsets></p></list-item><list-item><label><offsets xml_i="10927" xml_f="10930" txt_i="6166" txt_f="6169">(2)</offsets></label><p><offsets xml_i="10941" xml_f="10960" txt_i="6169" txt_f="6188">Ease of dilatation,</offsets></p></list-item><list-item><label><offsets xml_i="10994" xml_f="10997" txt_i="6189" txt_f="6192">(3)</offsets></label><p><offsets xml_i="11008" xml_f="11088" txt_i="6192" txt_f="6272">Subjective assessment of pain during dilatation using visual analog scale (VAS).</offsets></p></list-item></list><offsets xml_i="11111" xml_f="11112" txt_i="6273" txt_f="6274">
</offsets></p><p><offsets xml_i="11119" xml_f="11615" txt_i="6275" txt_f="6771">They were divided into four groups that are, no discomfort, mild discomfort, mild pain, moderate to severe pain. Those who had moderate to severe pain (VAS 5 or more) received either analgesia or anesthesia during further dilatation (up to Hegar's 8). Development of preoperative side effects such as nausea, vomiting, abdominal cramp, vaginal bleeding, pyrexia of significance, and loose motion was noted. Peroperative complications (cervical injury and uterine perforations) were also recorded.</offsets></p><sec id="sec2-1"><title><offsets xml_i="11643" xml_f="11663" txt_i="6772" txt_f="6792">Statistical analysis</offsets></title><p><offsets xml_i="11674" xml_f="11797" txt_i="6793" txt_f="6916">The data were analyzed using Medcalc 11.3.3.0 statistical software (MedCalc Software bvba, Acacialaan22, Ostend, Belgium) (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.medcalc.be"><offsets xml_i="11862" xml_f="11883" txt_i="6916" txt_f="6937">http://www.medcalc.be</offsets></ext-link><offsets xml_i="11894" xml_f="11947" txt_i="6937" txt_f="6990">). Statistical analysis included Chi-square test and </offsets><italic><offsets xml_i="11955" xml_f="11956" txt_i="6990" txt_f="6991">t</offsets></italic><offsets xml_i="11965" xml_f="12053" txt_i="6991" txt_f="7079">-test to compare the primary and secondary outcome between the study and control group. </offsets><italic><offsets xml_i="12061" xml_f="12062" txt_i="7079" txt_f="7080">P</offsets></italic><offsets xml_i="12071" xml_f="12124" txt_i="7080" txt_f="7130"> &lt; 0.05 were considered statistically significant.</offsets></p></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="12183" xml_f="12190" txt_i="7133" txt_f="7140">RESULTS</offsets></title><p><offsets xml_i="12201" xml_f="12687" txt_i="7141" txt_f="7627">At the beginning of the study, 312 patients were eligible for enrollment. 32 women not meeting the inclusion criteria or refusal to consent were excluded. A total of 280 women were randomized to Group A (study group) and Group B (control group) having 140 patients in each group. During follow-up, 5 in the study group and 7 in the control group were removed for not completing the intervention. 135 in the study group and 133 in the control group completed the study and were analyzed.</offsets></p><p><offsets xml_i="12694" xml_f="12785" txt_i="7628" txt_f="7719">Patients in both the group were comparable in relation to age, parity and body mass index [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="12817" xml_f="12824" txt_i="7719" txt_f="7726">Table 1</offsets></xref><offsets xml_i="12831" xml_f="12943" txt_i="7726" txt_f="7838">]. Different operative procedures and indications of hysteroscopy were comparable between the two groups [Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="12975" xml_f="12977" txt_i="7838" txt_f="7840">2a</offsets></xref><offsets xml_i="12984" xml_f="12989" txt_i="7840" txt_f="7845"> and </offsets><xref ref-type="table" rid="T3"><offsets xml_i="13021" xml_f="13022" txt_i="7845" txt_f="7846">b</offsets></xref><offsets xml_i="13029" xml_f="13098" txt_i="7846" txt_f="7915">]. The primary outcome of misoprostol administration is presented in </offsets><xref ref-type="table" rid="T4"><offsets xml_i="13130" xml_f="13137" txt_i="7915" txt_f="7922">Table 3</offsets></xref><offsets xml_i="13144" xml_f="13230" txt_i="7922" txt_f="8008">. Baseline cervical dilatation of 4.6 ± 0.96 mm in the study group was significantly (</offsets><italic><offsets xml_i="13238" xml_f="13239" txt_i="8008" txt_f="8009">P</offsets></italic><offsets xml_i="13248" xml_f="13376" txt_i="8009" txt_f="8134"> &lt; 0.0001) higher than the control group (3.6 ± 0.82 mm). Meantime needed for further cervical dilatation was significantly (</offsets><italic><offsets xml_i="13384" xml_f="13385" txt_i="8134" txt_f="8135">P</offsets></italic><offsets xml_i="13394" xml_f="13560" txt_i="8135" txt_f="8298"> &lt; 0.0001) delayed in the control group (study: 46.6 ± 14.57 s vs. control: 68.6 ± 14.3 s). Pain on cervical dilatation was significantly less in the study group (</offsets><italic><offsets xml_i="13568" xml_f="13569" txt_i="8298" txt_f="8299">P</offsets></italic><offsets xml_i="13578" xml_f="13591" txt_i="8299" txt_f="8309"> &lt; 0.05) [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="13623" xml_f="13630" txt_i="8309" txt_f="8316">Table 4</offsets></xref><offsets xml_i="13637" xml_f="13642" txt_i="8316" txt_f="8321"> and </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13672" xml_f="13680" txt_i="8321" txt_f="8329">Figure 1</offsets></xref><offsets xml_i="13687" xml_f="13884" txt_i="8329" txt_f="8526">]. Perioperative side effects of which preoperative abdominal cramp and nausea vomiting were significantly higher in study group although these effects did not lead to any prolonged hospital stay [</offsets><xref ref-type="table" rid="T6"><offsets xml_i="13916" xml_f="13923" txt_i="8526" txt_f="8533">Table 5</offsets></xref><offsets xml_i="13930" xml_f="13932" txt_i="8533" txt_f="8535">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="13980" xml_f="13987" txt_i="8536" txt_f="8543">Table 1</offsets></label><caption><p><offsets xml_i="14007" xml_f="14041" txt_i="8543" txt_f="8577">Patient profile (age, parity, BMI)</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g001"></graphic></table-wrap><table-wrap id="T2" position="float"><label><offsets xml_i="14161" xml_f="14169" txt_i="8578" txt_f="8586">Table 2a</offsets></label><caption><p><offsets xml_i="14189" xml_f="14225" txt_i="8586" txt_f="8622">Operative procedures and indications</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g002"></graphic></table-wrap><table-wrap id="T3" position="float"><label><offsets xml_i="14345" xml_f="14353" txt_i="8623" txt_f="8631">Table 2b</offsets></label><caption><p><offsets xml_i="14373" xml_f="14401" txt_i="8631" txt_f="8659">Indications for hysteroscopy</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g003"></graphic></table-wrap><table-wrap id="T4" position="float"><label><offsets xml_i="14521" xml_f="14528" txt_i="8660" txt_f="8667">Table 3</offsets></label><caption><p><offsets xml_i="14548" xml_f="14585" txt_i="8667" txt_f="8704">Results of misoprostol administration</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g004"></graphic></table-wrap><table-wrap id="T5" position="float"><label><offsets xml_i="14705" xml_f="14712" txt_i="8705" txt_f="8712">Table 4</offsets></label><caption><p><offsets xml_i="14732" xml_f="14788" txt_i="8712" txt_f="8768">Subjective assessment of pain during cervical dilatation</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g005"></graphic></table-wrap><fig id="F1" position="float"><label><offsets xml_i="14901" xml_f="14909" txt_i="8769" txt_f="8777">Figure 1</offsets></label><caption><p><offsets xml_i="14929" xml_f="14974" txt_i="8777" txt_f="8822">Assessment of pain during cervical dilatation</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g006"></graphic></fig><table-wrap id="T6" position="float"><label><offsets xml_i="15087" xml_f="15094" txt_i="8823" txt_f="8830">Table 5</offsets></label><caption><p><offsets xml_i="15114" xml_f="15139" txt_i="8830" txt_f="8855">Perioperative side effect</offsets></p></caption><graphic xlink:href="JNSBM-6-123-g007"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="15267" xml_f="15277" txt_i="8857" txt_f="8867">DISCUSSION</offsets></title><p><offsets xml_i="15288" xml_f="15739" txt_i="8868" txt_f="9319">Cervical priming prior to gynecological procedures facilitates the operation and decreases the risk of cervical, uterine injury that are often associated with the mechanical dilatation. Various prostaglandin preparations, laminaria tents are commonly used for cervical priming. Cervical injury, uterine perforations, pain due to cervical dilatation despite local anesthesia and precise technique are the major problem associated with these procedures.</offsets></p><p><offsets xml_i="15746" xml_f="15908" txt_i="9320" txt_f="9482">The off-label use of misoprostol for gynecological indications has received less attention, despite reports of its effectiveness in inducing cervical dilatation.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="15941" xml_f="15942" txt_i="9482" txt_f="9483">7</offsets></xref><xref rid="ref8" ref-type="bibr"><offsets xml_i="15982" xml_f="15983" txt_i="9483" txt_f="9484">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="16023" xml_f="16024" txt_i="9484" txt_f="9485">9</offsets></xref><offsets xml_i="16031" xml_f="16209" txt_i="9485" txt_f="9663">] Indeed oral or vaginal misoprostol application before hysteroscopy resulted in greater cervical dilatation, decreased cervical resistance and less need for further dilatation.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="16243" xml_f="16245" txt_i="9663" txt_f="9665">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="16286" xml_f="16288" txt_i="9665" txt_f="9667">11</offsets></xref><xref rid="ref12" ref-type="bibr"><offsets xml_i="16329" xml_f="16331" txt_i="9667" txt_f="9669">12</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="16372" xml_f="16374" txt_i="9669" txt_f="9671">13</offsets></xref><offsets xml_i="16381" xml_f="16658" txt_i="9671" txt_f="9948">] In the present study, as well misoprostol treated women had significantly increased baseline cervical dilatation. Resistance to cervical dilatation and mean time taken for dilatation was less in misoprostol group when compared with control group. Which is in contrast to Dan </offsets><italic><offsets xml_i="16666" xml_f="16671" txt_i="9948" txt_f="9953">et al</offsets></italic><offsets xml_i="16680" xml_f="16682" txt_i="9953" txt_f="9955">.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="16716" xml_f="16718" txt_i="9955" txt_f="9957">14</offsets></xref><offsets xml_i="16725" xml_f="16739" txt_i="9957" txt_f="9971">] and Perrone </offsets><italic><offsets xml_i="16747" xml_f="16752" txt_i="9971" txt_f="9976">et al</offsets></italic><offsets xml_i="16761" xml_f="16763" txt_i="9976" txt_f="9978">.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="16797" xml_f="16799" txt_i="9978" txt_f="9980">15</offsets></xref><offsets xml_i="16806" xml_f="16987" txt_i="9980" txt_f="10161">] reporting no priming effect of misoprostol on premenopausal cervix and rather misoprostol use causing more pain, uterine cramping, and vaginal bleeding. Likewise, Bunnasathiansri </offsets><italic><offsets xml_i="16995" xml_f="17000" txt_i="10161" txt_f="10166">et al</offsets></italic><offsets xml_i="17009" xml_f="17012" txt_i="10166" txt_f="10169">.,[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="17046" xml_f="17048" txt_i="10169" txt_f="10171">16</offsets></xref><offsets xml_i="17055" xml_f="17062" txt_i="10171" txt_f="10178">] Fung </offsets><italic><offsets xml_i="17070" xml_f="17075" txt_i="10178" txt_f="10183">et al</offsets></italic><offsets xml_i="17084" xml_f="17086" txt_i="10183" txt_f="10185">.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="17120" xml_f="17122" txt_i="10185" txt_f="10187">17</offsets></xref><offsets xml_i="17129" xml_f="17383" txt_i="10187" txt_f="10441">] also did not observe any significant benefit from applying misoprostol in postmenopausal women. This might however, be due to hypo estrogenic state as pretreatment with estrogen facilitated misoprostol-induced cervical priming in postmenopausal women.[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="17417" xml_f="17419" txt_i="10441" txt_f="10443">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="17460" xml_f="17462" txt_i="10443" txt_f="10445">19</offsets></xref><offsets xml_i="17469" xml_f="17470" txt_i="10445" txt_f="10446">]</offsets></p><p><offsets xml_i="17477" xml_f="17958" txt_i="10447" txt_f="10928">Different studies had used misoprostol in different dose and routes of administration. The dose varied from 100 to 1000 μg and duration of insertion before procedures varied from 2 to 12 h. A single dose 400 μg misoprostol given vaginally 3 h prior to intervention seems to given the best efficacy with least side effects, however this is contradicted by study reporting similar effects achieved by all three routes of misoprostol application (i.e., oral, vaginal and sublingual).[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="17992" xml_f="17994" txt_i="10928" txt_f="10930">20</offsets></xref><offsets xml_i="18001" xml_f="19473" txt_i="10930" txt_f="12402">] In our study, we used 400 μg single dose of misoprostol by vaginal route 6 h prior to the procedures as a cervical priming agent. Our aim was to see the effectiveness of misoprostol by this approach. Though diagnostic hysteroscopy could be done using 4 mm scope without anesthesia in many cases. However, in nulliparous and elderly women introduction of hysteroscope without prior dilatation may cause difficulties. In this study, we have used larger size hysteroscope with an intention to perform minor operative procedures such as removal of Copper T, endometrial biopsy etc., if required, at the same sitting. As vaginal misoprostol was found to be effective as a cervical priming agent in nonpregnant premenopausal women in our study, this approach could be applied before operative hysteroscopy procedures. Moreover, the use of misoprostol as cervical priming agent reduces the requirement of analgesia or anesthesia during the hysteroscopy procedures thereby minimizing the complications and cost associated with treatment. Nevertheless, prior hospitalization was required to apply vaginal misoprostol, and this was the only limitation of this study. Self-vaginal application or sublingual route may be the solution of address this problem, which needs further evaluation. We conclude that misoprostol is effective in increasing cervical dilatation, decreasing both cervical resistance and need for additional dilatation before hysteroscopy in premenopausal women.</offsets></p><sec id="sec2-2"><title><offsets xml_i="19501" xml_f="19534" txt_i="12403" txt_f="12436">Financial support and sponsorship</offsets></title><p><offsets xml_i="19545" xml_f="19549" txt_i="12437" txt_f="12441">Nil.</offsets></p></sec><sec id="sec2-3"><title><offsets xml_i="19583" xml_f="19604" txt_i="12443" txt_f="12464">Conflicts of interest</offsets></title><p><offsets xml_i="19615" xml_f="19650" txt_i="12465" txt_f="12500">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmeyr</surname><given-names>GJ</given-names></name><name><surname>Gülmezoglu</surname><given-names>AM</given-names></name><name><surname>Alfirevic</surname><given-names>Z</given-names></name></person-group><article-title>Misoprostol for induction of labour: A systematic review</article-title><source>Br J Obstet Gynaecol</source><year>1999</year><volume>106</volume><fpage>798</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">10453829</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecatti</surname><given-names>JG</given-names></name><name><surname>Tedesco</surname><given-names>RP</given-names></name><name><surname>Pires</surname><given-names>HM</given-names></name><name><surname>Calderon</surname><given-names>IM</given-names></name><name><surname>Faúndes</surname><given-names>A</given-names></name></person-group><article-title>Effectiveness and safety of a new vaginal misoprostol product specifically labeled for cervical ripening and labor induction</article-title><source>Acta Obstet Gynecol Scand</source><year>2006</year><volume>85</volume><fpage>706</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16752263</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahu</surname><given-names>L</given-names></name><name><surname>Chakravertty</surname><given-names>B</given-names></name></person-group><article-title>Comparison of prostaglandin E 1 (misoprostol) with prostaglandin E 2 (dinoprostone) for labor induction</article-title><source>J Obstet Gynecol India</source><year>2004</year><volume>54</volume><fpage>139</fpage><lpage>42</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakhare</surname><given-names>AP</given-names></name><name><surname>Mahale</surname><given-names>AR</given-names></name><name><surname>Kardile</surname><given-names>GP</given-names></name></person-group><article-title>Vaginal misoprostol for medical evacuation of missed abortion</article-title><source>J Obstet Gynecol India</source><year>2005</year><volume>55</volume><fpage>178</fpage><lpage>9</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenore</surname><given-names>JL</given-names></name></person-group><article-title>Methods for cervical ripening and induction of labor</article-title><source>Am Fam Physician</source><year>2003</year><volume>67</volume><fpage>2123</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12776961</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>GG</given-names></name><name><surname>Wan</surname><given-names>SR</given-names></name></person-group><article-title>Drug therapy during labor and delivery, part 2</article-title><source>Am J Health Syst Pharm</source><year>2006</year><volume>63</volume><fpage>1131</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16754739</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngai</surname><given-names>SW</given-names></name><name><surname>Chan</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>KL</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><article-title>Oral misoprostol for cervical priming in non-pregnant women</article-title><source>Hum Reprod</source><year>1997</year><volume>12</volume><fpage>2373</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9436666</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preutthipan</surname><given-names>S</given-names></name><name><surname>Herabutya</surname><given-names>Y</given-names></name></person-group><article-title>Vaginal misoprostol for cervical priming before operative hysteroscopy: A randomized controlled trial</article-title><source>Obstet Gynecol</source><year>2000</year><volume>96</volume><fpage>890</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11084173</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preutthipan</surname><given-names>S</given-names></name><name><surname>Herabutya</surname><given-names>Y</given-names></name></person-group><article-title>A randomized comparison of vaginal misoprostol and dinoprostone for cervical priming in nulliparous women before operative hysteroscopy</article-title><source>Fertil Steril</source><year>2006</year><volume>86</volume><fpage>990</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16949590</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oppegaard</surname><given-names>KS</given-names></name><name><surname>Nesheim</surname><given-names>BI</given-names></name><name><surname>Istre</surname><given-names>O</given-names></name><name><surname>Qvigstad</surname><given-names>E</given-names></name></person-group><article-title>Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design</article-title><source>BJOG</source><year>2007</year><volume>114</volume><fpage>769</fpage><series>e1-12</series><pub-id pub-id-type="pmid">17516971</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oppegaard</surname><given-names>KS</given-names></name><name><surname>Nesheim</surname><given-names>BI</given-names></name><name><surname>Istre</surname><given-names>O</given-names></name><name><surname>Qvigstad</surname><given-names>E</given-names></name></person-group><article-title>Comparison of self-administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design</article-title><source>BJOG</source><year>2008</year><volume>115</volume><fpage>663</fpage><series>e1-9</series><pub-id pub-id-type="pmid">18201279</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batukan</surname><given-names>C</given-names></name><name><surname>Ozgun</surname><given-names>MT</given-names></name><name><surname>Ozcelik</surname><given-names>B</given-names></name><name><surname>Aygen</surname><given-names>E</given-names></name><name><surname>Sahin</surname><given-names>Y</given-names></name><name><surname>Turkyilmaz</surname><given-names>C</given-names></name></person-group><article-title>Cervical ripening before operative hysteroscopy in premenopausal women: A randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol</article-title><source>Fertil Steril</source><year>2008</year><volume>89</volume><fpage>966</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">17681307</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barcaite</surname><given-names>E</given-names></name><name><surname>Bartusevicius</surname><given-names>A</given-names></name><name><surname>Railaite</surname><given-names>DR</given-names></name><name><surname>Nadisauskiene</surname><given-names>R</given-names></name></person-group><article-title>Vaginal misoprostol for cervical priming before hysteroscopy in perimenopausal and postmenopausal women</article-title><source>Int J Gynaecol Obstet</source><year>2005</year><volume>91</volume><fpage>141</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16102766</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname><given-names>Yu</given-names></name><name><surname>Li</surname><given-names>TC</given-names></name><name><surname>Xia</surname><given-names>E</given-names></name><name><surname>Xiaowu</surname><given-names>H</given-names></name></person-group><article-title>A prospective randomized controlled trial comparing vaginal misoprostol and osmotic dilator in achieving cervical ripening before operative hysteroscopy</article-title><source>Gynecol Surg</source><year>2006</year><volume>3</volume><fpage>186</fpage><lpage>9</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>JF</given-names></name><name><surname>Caldito</surname><given-names>G</given-names></name><name><surname>Mailhes</surname><given-names>JB</given-names></name><name><surname>Tucker</surname><given-names>AN</given-names></name><name><surname>Ford</surname><given-names>WR</given-names></name><name><surname>London</surname><given-names>SN</given-names></name></person-group><article-title>Oral misoprostol before office endometrial biopsy</article-title><source>Obstet Gynecol</source><year>2002</year><volume>99</volume><fpage>439</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">11864671</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunnasathiansri</surname><given-names>S</given-names></name><name><surname>Herabutya</surname><given-names>Y</given-names></name><name><surname>O-Prasertsawat</surname><given-names>P</given-names></name></person-group><article-title>Vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women: A randomized controlled trial</article-title><source>J Obstet Gynaecol Res</source><year>2004</year><volume>30</volume><fpage>221</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15210047</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>TM</given-names></name><name><surname>Lam</surname><given-names>MH</given-names></name><name><surname>Wong</surname><given-names>SF</given-names></name><name><surname>Ho</surname><given-names>LC</given-names></name></person-group><article-title>A randomised placebo-controlled trial of vaginal misoprostol for cervical priming before hysteroscopy in postmenopausal women</article-title><source>BJOG</source><year>2002</year><volume>109</volume><fpage>561</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12066947</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oppegaard</surname><given-names>KS</given-names></name><name><surname>Lieng</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>A</given-names></name><name><surname>Istre</surname><given-names>O</given-names></name><name><surname>Qvigstad</surname><given-names>E</given-names></name><name><surname>Nesheim</surname><given-names>BI</given-names></name></person-group><article-title>A combination of misoprostol and estradiol for preoperative cervical ripening in postmenopausal women: A randomised controlled trial</article-title><source>BJOG</source><year>2010</year><volume>117</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">20002369</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atmaca</surname><given-names>R</given-names></name><name><surname>Kafkasli</surname><given-names>A</given-names></name><name><surname>Burak</surname><given-names>F</given-names></name><name><surname>Germen</surname><given-names>AT</given-names></name></person-group><article-title>Priming effect of misoprostol on estrogen pretreated cervix in postmenopausal women</article-title><source>Tohoku J Exp Med</source><year>2005</year><volume>206</volume><fpage>237</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15942151</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YY</given-names></name><name><surname>Kim</surname><given-names>TJ</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Choi</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>BG</given-names></name><etal></etal></person-group><article-title>The use of misoprostol before hysteroscopic surgery in non-pregnant premenopausal women: A randomized comparison of sublingual, oral and vaginal administrations</article-title><source>Hum Reprod</source><year>2010</year><volume>25</volume><fpage>1942</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20542898</pub-id></element-citation></ref></ref-list></back></article>